NEWSNATIONNOW (Taylor Delandro) - Are GLP-1s pushing plus-size clothing off of store shelves?
Experts say there isn't enough evidence to prove weight-loss drugs are the sole reason retailers are reducing larger sizes.
YOUTUBE (NewsNation) - GLP-1 Wellness Retreats: The New Luxury Weight Loss Trend? | Hot Take with Jesse Weber
Luxury wellness retreats are being designed around people who use or are considering medications such as Ozempic, Wegovy, Mounjaro and Zepbound. Think sunrise yoga, protein-focused meals, strength training and life coaching, all for $12,000 a week. On Thursday's “Hot Take with Jesse Weber,” we break down whether these retreats provide the long-term support GLP-1 users need or whether the luxury wellness industry has found its next expensive cash cow. We'll also examine why GLP-1 use has nearly quadrupled in the past two years. Then, we're joined by Jill Boyd, COO of Hilton Head Health, one of the resorts now offering a specialized GLP-1 experience, to discuss the cost, medical oversight and value.
THENATIONALPULSE (Pulse Wires) - Medicare Launches New Weight Loss Drug Pipeline.
Medicare's first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost.
Medicare’s new weight-loss drug program offers affordable access to GLP-1 medication for seniors, marking a significant shift in healthcare coverage and efforts to combat obesity . PULSE POINTS WHAT HAPPENED: Medicare’s first-of-its-kind weight-loss drug program has officially launched, giving American seniors access to GLP-1 drugs at a subsidized cost. DETAIL: On Wednesday, Medicare & Medicaid Services launched a new program allowing Americans aged 65 and older to access weight-loss drugs at a reduced cost of $50 a month, starting with an 18-month trial period. This is the first time Medicare has offered coverage for GLP-1 weight-loss drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo and Zepbound. Previously,…Open
NYTIMES (Dani Blum) - What Older Adults Should Know About GLP-1 Drugs as Medicare Coverage Expands
A Medicare pilot beginning Wednesday will broaden access to medications like Wegovy and Zepbound. There are unique risks for those over 65.
YOUTUBE (Newsmax) - BONUS: Dr. Jen Ashton on GLP-1s and the Future of Weight-Loss Medicine | Greta Wire
Could GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound be far more than weight-loss drugs? In this special bonus episode of Greta Wire, Greta Van Susteren is joined by Dr. Jen Ashton on NEWSMAX TV’s The Record with Greta Van Susteren to discuss a new study suggesting GLP-1 drugs may be associated with reduced cancer progression in several obesity-related cancers. Dr. Ashton explains what the study found, what it does — and does not — prove, and why researchers are now looking at GLP-1 medications for possible effects on inflammation, the immune system, cancer spread, recurrence, and prevention. Greta also presses on the insurance question: if these drugs may help prevent expensive and devastating medical complications,…
AXIOS (Tina Reed) - Medicare weight-loss drug coverage could overwhelm doctors
Next month's launch of a Medicare program providing weight-loss drugs for $50 a month is expected to unleash pent-up demand for Wegovy, Zepbound and other blockbuster treatments — and create new bottlenecks at doctors' offices. The big picture: It could become one of the biggest drug rollouts ever — and it could test an already burdened system as seniors seek new GLP-1 prescriptions. - Clinicians worry that could also give short shrift to patient counseling on how to take the injectables and pills, adjust dosages and deal with side effects. - Medicare has been prohibited by law from covering weight-loss drugs. Where it stands: The new program is part of a deal President Trump struck with Eli Lilly and Novo Nordisk to cut prices for…
NPR (Yuki Noguchi) - Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it
A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs.
NPR (Yuki Noguchi) - What does a 'GLP-1 Friendly' diet look like? We asked nutritionists
Big food companies are starting to market to people on the powerful new obesity meds with labels that say "GLP-1 Friendly." Nutritionists help us decode that message.
NYTIMES (Simar Bajaj and Dani Blum) - When Weight-Loss Drugs Don’t Work
Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call “non-responders.”
WASHINGTONPOST (Christopher Rowland) - How GLP1s are changing the ways Americans buy medicine
Consumers are paying in cash in a hotly competitive marketplace, creating a rare phenomenon for a relatively new class of prescription drugs: falling prices.